Sevelamer

Drugbox


width=200
IUPAC_name = poly(allylamine-
co-"N","N"'-diallyl-1,3-diamino-2-hydroxypropane)
CAS_number = 52757-95-6
ATC_prefix = V03
ATC_suffix = AE02
PubChem = 3085017
DrugBank = APRD01226
chemical_formula = [(C₃H₇N)_a+b.(C₉H₁₇N₂O)_c] _m
where a+b:c = 9:1
molecular_weight = variable
bioavailability = nil
metabolism = nil
elimination_half-life = n/a
excretion = faecal 100%
pregnancy_category = B3 (Australia), C (US)
legal_status = Schedule 4 (Australia), Rx only (US)
routes_of_administration = oral

Sevelamer (rINN) (pronEng|sɛˈvɛləmɚ/, /-mɪr) is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade names Renagel and Renvela (carbonate formulation).

Chemistry and pharmacology

Sevelamer is a copolymer of 2-(chloromethyl)oxirane (epichlorohydrin) and prop-2-en-1-amine. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphorus molecules through ionic and hydrogen bonding.

Clinical use

Indications

Sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic renal failure (end stage renal disease).

Contraindications

Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.

Adverse effects

Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.

External links

* [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601248.html Sevelamer] - medlineplus.org
* [http://www.renagel.com/ Renagel] - genzyme.com
* [http://www.renvela.com/ Renvela] - genzyme.com